相关实验视频
Updated: Jul 16, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.5K
患者对辅助帕金森病治疗的偏好:一个离散选择实验
Michael Serbin1, Connie Marras2, Carol Mansfield3
1Neurocrine Biosciences, Inc., San Diego, CA, USA.
Patient preference and adherence
|September 19, 2023
概括
患有帕金森病 (PD) 的人想要更多的ON时间,并会交易一些ON时间来避免药物的副作用. 辅助疗法比不使用药物更好.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 患者报告的结果
背景情况:
- 乐伏多巴/卡比多巴 (LD/CD) 治疗是帕金森病 (PD) 的标准治疗方法.
- 标志着症状复发的OFF发作会破坏治疗的有效性.
- 辅助药物旨在减少OFF时间并改善日常功能.
研究的目的:
- 调查患者对帕金森病 (PD) 辅助药物的偏好.
- 了解PD患者如何权衡辅助疗法的益处 (增加ON时间) 与负担 (副作用,剂量频率).
主要方法:
- 一项离散选择实验调查对美国患有PD的成年人进行了管理,他们经历了OFF插曲.
- 参与者评估了假设的治疗概况,其有效性,不良反应 (失眠症,腹,体液颜色变化) 和剂量各不相同.
- 随机参数逻辑模型用于数据分析.
主要成果:
- 患者需要至少额外60分钟的ON时间来接受40%的体液颜色变化风险或10分钟的运动障碍.
- 10%的腹风险需要40分钟的额外启动时间;切换药物的频率需要22分钟.
- 辅助药物是首选的,而不是没有药物,假设的阿皮卡类治疗是最喜欢的选择.
结论:
- 帕金森病患者优先增加ON时间,但愿意接受更少的ON时间,以避免特定的不良影响.
- 患者的偏好表明对辅助疗法的需求,这些辅助疗法平衡了有效性和耐受性.
相关概念视频
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Parkinson's Disease: Overview
592
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592
Direct-Acting Cholinergic Agonists: Therapeutic Uses
790
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
790
Cholinergic Antagonists: Therapeutic Uses
775
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
775
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.3K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K

